Prostate Cancer International is
for 2011 by Great NonProfits
Here’s a link to an excellent article on the “real” abiraterone story, written by journalist Robert Sandall, who has advanced prostate cancer himself. He has spoken to researcher Johann de Bono directly, and quotes him as follows: Some parts of the press have hyped this drug way beyond what I said about it. … This is [...]
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cancer, hormone, prostate, refractory | 4 Comments »
In additional news breaking today: Dendreon Corp. is predicting interim results of the IMPACT study of Provenge in metastatic, androgen-independent prostate cancer by October 2008 The FDA has refused to approve an experimental, topical treatment for erectile dysfunction
Filed under: Drugs in development, Management, Treatment | Tagged: cancer vaccine, Dendreon, ED, erectile dysfunction, hormone, NexMed, prostate, Provenge, refractory | Leave a Comment »
A paper published today in the Journal of Clinical Oncology suggests that a new agent has been identified for the treatment of end-stage prostate cancer. The paper is being quoted in the media and is likely to reinvigorate discussion about the merits and risks of agents targeting hormone synthetic pathways.
Filed under: Management, Treatment, Drugs in development | Tagged: abiraterone, cancer, deprivation, flutamide, hormone, prostate, PSA | 10 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site